Latest On Accelerate Diagnostics, Inc (AXDX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-12 06:43 EST | News | Accelerate Diagnostics, Inc. (AXDX) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-11 17:07 EST | News | Accelerate Diagnostics GAAP EPS of -$0.17 misses by $0.03, revenue of $2.81M misses by $0.54M | N/A | |
| 2023-05-11 02:25 EST | News | Accelerate Diagnostics Q1 2023 Earnings Preview | N/A | |
| 2023-03-31 01:41 EST | News | Accelerate Diagnostics surges ~25% as FY22 revenue climbs, loss narrows | N/A | |
| 2023-03-30 01:18 EST | News | Accelerate Diagnostics GAAP EPS of -$0.76 in-line, revenue of $12.75M beats by $0.1M | N/A | |
About Accelerate Diagnostics, Inc (AXDX):
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate read more... Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
General
- Name Accelerate Diagnostics, Inc
- Symbol AXDX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDiagnostics & Research
- Full Time Employees 224
- Fiscal Year EndDecember
- IPO Date1996-11-18
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryLife Sciences Tools & Services
- Gic SubIndustryLife Sciences Tools & Services
- Web URLhttp://acceleratediagnostics.com
Valuation
- Price/Sales (Trailing 12 Mt.) 46.15
- Enterprise Value Revenue 56.2
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.30
- Next Year EPS Estimate -$1.08
- Next Quarter EPS Estimate -$0.32
- Operating Margin -567%
- Return on Assets -35%
- Revenue 11.17 million
- Earnings Per Share -$1.60
- Revenue Per Share $0.2
- Gross Profit 4.46 million
- Quarterly Earnings Growth -10.4%
Highlights
- Market Capitalization 545.8 million
- EBITDA -73321000
- PEG Ratio -0.55
- Analyst Target Price $12.33
- Book Value Per Share $0.19
Share Statistics
- Shares Outstanding 59.33 million
- Shares Float 30.19 million
- % Held by Insiders 4051%
- % Held by Institutions 52.17%
- Shares Short 8.77 million
- Shares Short Prior Month 9.58 million
- Short Ratio 8.75
- Short % of Float 25%
- Short % of Shares Outstanding 15%
Technicals
- Beta 2.13
- 52 Week High $19.11
- 52 Week Low $4.75
- 50 Day Moving Average 11.02
- 200 Day Moving Average 9.84
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Accelerate Diagnostics, Inc (AXDX) Dividend Calendar:
Accelerate Diagnostics, Inc (AXDX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Accelerate Diagnostics, Inc (AXDX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Accelerate Diagnostics, Inc (AXDX) Chart:
Accelerate Diagnostics, Inc (AXDX) News:
Below you will find a list of latest news for Accelerate Diagnostics, Inc (AXDX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Accelerate Diagnostics, Inc (AXDX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest AXDX Trades:
Accelerate Diagnostics, Inc (AXDX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 8-K (Current report) | |
| 2020-11-06 | 8-K (Current report) | |
| 2020-11-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-09-21 | 8-K (Current report) | |
| 2020-08-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-27 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-18 | 8-K (Current report) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-05 | SD () | |
| 2020-07-31 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-07-06 | 8-K (Current report) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-26 | 8-K (Current report) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-16 | 4 (Statement of changes in beneficial ownership of securities) | |
Accelerate Diagnostics, Inc (AXDX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Accelerate Diagnostics, Inc (AXDX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 4051%
Institutional Ownership: 5217%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-06-18 | ROMNEY HUMPHRIES | Chief Scientific Officer | Sell | 3,000.00 | 12.00 | 36,000.00 | 0.00 | |
| 2020-06-18 | ROMNEY HUMPHRIES | Chief Scientific Officer | Buy | 3,000.00 | 5.93 | 17,790.00 | 3,000.00 | |
| 2020-06-17 | ROMNEY HUMPHRIES | Chief Scientific Officer | Sell | 2,000.00 | 11.75 | 23,500.00 | 0.00 | |
| 2020-06-17 | ROMNEY HUMPHRIES | Chief Scientific Officer | Buy | 2,000.00 | 5.93 | 11,860.00 | 2,000.00 | |
| 2020-06-16 | ROMNEY HUMPHRIES | Chief Scientific Officer | Sell | 4,000.00 | 11.00 | 44,000.00 | 0.00 | |
| 2020-06-16 | ROMNEY HUMPHRIES | Chief Scientific Officer | Buy | 4,000.00 | 5.93 | 23,720.00 | 4,000.00 | |
| 2020-06-15 | JACK W SCHULER | Director | Buy | 95,492.00 | 9.86 | 941,551.12 | 16,603,524.00 | |
| 2020-06-12 | JACK W SCHULER | Director | Buy | 134,080.00 | 9.34 | 1,252,307.20 | 16,508,032.00 | |
| 2020-06-11 | JACK W SCHULER | Director | Buy | 129,000.00 | 9.18 | 1,184,220.00 | 16,373,952.00 | |
| 2020-06-10 | JACK W SCHULER | Director | Buy | 100,000.00 | 9.84 | 984,000.00 | 16,244,952.00 | |
| 2020-06-09 | JACK W SCHULER | Director | Buy | 180,955.00 | 9.63 | 1,742,596.65 | 16,144,952.00 | |
| 2020-06-05 | JACK W SCHULER | Director | Buy | 1,100,000.00 | 8.58 | 9,438,000.00 | 15,963,997.00 | |
| 2020-05-13 | JACK W SCHULER | Director | Buy | 89,055.00 | 9.46 | 842,460.30 | 14,863,997.00 | |
| 2020-05-12 | JACK W SCHULER | Director | Buy | 20,000.00 | 9.92 | 198,400.00 | 14,774,942.00 | |
| 2020-05-11 | JACK W SCHULER | Director | Buy | 20,000.00 | 9.99 | 199,800.00 | 14,754,942.00 | |
| 2020-05-07 | JACK W SCHULER | Director | Buy | 25,000.00 | 9.87 | 246,750.00 | 14,734,942.00 | |
| 2020-05-06 | JACK W SCHULER | Director | Buy | 10,868.00 | 10.00 | 108,680.00 | 14,709,942.00 | |
| 2020-05-05 | JACK W SCHULER | Director | Buy | 8,625.00 | 10.00 | 86,250.00 | 14,699,074.00 | |
| 2020-05-04 | JACK W SCHULER | Director | Buy | 1,204.00 | 9.98 | 12,015.92 | 14,690,449.00 | |
| 2020-05-01 | JACK W SCHULER | Director | Buy | 4,000.00 | 10.03 | 40,120.00 | 14,689,245.00 | |